Calciscon delivers breakthrough
Diagnostics for Calciprotein
Particles (CPP), potent drivers
of inflammation in multiple
CALCISCON is the world leader in the
development of methods to measure
Calciprotein Particles (CPP) and in
their translation into new products for
clinical use. Calciscon offers the most
comprehensive panel of measurement
methods relative to CPP.
Calciprotein Particles (CPP) are a recently discovered class of circulating species recognized
as potent endogenous drivers of inflammation, oxidative stress and calcification.
For example Calciprotein Particles are crucially involved in the progression of chronic kidney
disease (CKD), and its resulting cardiovascular morbidity and mortality.
Calciscon is initially launching the T50 Calciprotein Crystallization test (T50® test) to
improve the quality of life of patients suffering from end-stage kidney disease.
Further products are under development.
Based on our unique expertise, expansion towards therapeutics is planned.
CEO Vincent Linder, Ph.D.
Serial Entrepreneur in IVD (USA and Europe),
product dev. (CE & FDA), exit (M&A)
FOUNDER, PRESIDENT, CMO PROF Andreas Pasch, MD
Scientist and Practicing Nephrologist; Inventor
of the T50 test; Expert in clinical use of T50/CPP
Non-Executive Director Chan-Yuan Lu
10+ year of global expertise in the
VC industry (USA, Taiwan, Europe)
Non-Executive Director Karsten Uhlmann
Managing owner of
international brewing group
and senior entrepreneur
Non-Executive Director Peter Steinmann
Past Pres. Ethicon-Endo Surgery (J&J)
Europe, Corp. VP Medtronic Europe
ADVISOR PROF Edward Smith, PH.D.
Inventor of CPP assay,
Expert in CPP biology
DIRECTOR IVD Didier Falconnet, PH.D.
Past Director IVD at GSK, and Previous R&D
leader in 2 startups (with 1 IPO)
QUALITY ASSURANCE SPECIALIST Caroline Müssig
Specialization in medical devices